Retatrutide

What Is Retatrutide?

Retatrutide (LY-3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly, currently in Phase 3 clinical trials for elevated adiposity, metabolic dysregulation, and type 2 diabetes. It represents the next generation of metabolic therapeutics — moving beyond the single or dual-pathway mechanisms of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) to simultaneously activate three distinct metabolic hormone receptors. Retatrutide is the first triple agonist targeting GLP-1, GIP, and glucagon receptors with published phase 2 clinical data (Jastreboff et al., NEJM, 2023).

"Once-weekly treatment with retatrutide resulted in substantial, dose-dependent weight reduction at 24 and 48 weeks." — Jastreboff et al., NEJM (2023)

Retatrutide activates:

• GLP-1 (Glucagon-Like Peptide-1) — appetite suppression and insulin secretion
• GIP (Glucose-Dependent Insulinotropic Polypeptide) — enhanced insulin response and metabolic efficiency
• Glucagon receptor — increased energy expenditure and fat mobilisation

This triple-agonist mechanism produces metabolic effects that substantially exceed those of earlier single or dual-pathway agents. Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) documented body mass reductions approaching 24% of baseline body weight at 48 weeks in participants receiving the highest dose — among the largest body mass reduction outcomes ever observed in a metabolic pharmacotherapy trial.

Retatrutide is administered as a once-weekly subcutaneous injection, consistent with other incretin-based therapies.

---

How It Works — Mechanism of Action

1. GLP-1 Receptor Agonism — Appetite & Insulin GLP-1 receptor activation suppresses appetite by acting on hypothalamic satiety centres, slows gastric emptying (prolonging satiety), and stimulates glucose-dependent insulin secretion. This is the mechanism shared with semaglutide — Retatrutide's GLP-1 component alone would produce clinically significant body mass reduction.

2. GIP Receptor Agonism — Metabolic Amplification GIP receptor activation potentiates insulin secretion, enhances GLP-1 sensitivity, and supports fat cell (adipocyte) metabolism. The addition of GIP agonism is what distinguishes tirzepatide from semaglutide and underpins its superior efficacy — Retatrutide builds on this with a third mechanism.

3. Glucagon Receptor Agonism — Energy Expenditure The addition of glucagon receptor activation is Retatrutide's most significant differentiator. Glucagon increases hepatic glucose production and, critically, increases energy expenditure — the body burns more calories at rest. It also directly promotes lipolysis (fat breakdown) in adipose tissue. The challenge with glucagon alone is that it raises blood glucose — Retatrutide's GLP-1 component counteracts this, allowing the energy-expenditure benefits of glucagon without hyperglycaemia.

The synergy: GLP-1 suppresses appetite and manages insulin. GIP amplifies the insulin response and enhances metabolic efficiency. Glucagon raises energy expenditure and promotes lipid mobilisation. Together they attack weight and metabolic disease from three distinct angles simultaneously.

Preclinical studies demonstrated that retatrutide's triple agonism produces superior efficacy at lower doses compared with dual agonists targeting GLP-1/GIP or GLP-1/glucagon alone (Jastreboff et al., NEJM, 2023). The addition of glucagon receptor agonism to the GLP-1/GIP dual mechanism is what distinguishes retatrutide from tirzepatide, potentially offering additional metabolic and hepatoprotective benefits (Jastreboff et al., NEJM, 2023).

---

Research-Backed Benefits

Significant Body Mass Reduction in Clinical Research

• Participants receiving 12 mg/week achieved mean body mass reductions approaching 24% of baseline body weight at 48 weeks
• Results exceed outcomes from any currently approved GLP-1 or GIP/GLP-1 agonist
• Body mass reduction was dose-dependent: 1–4 mg produced 8–12% reduction; 8 mg produced greater reduction; 12 mg produced the most dramatic outcomes
• The phase 2 trial demonstrated a mean weight reduction of up to 24.2% at 48 weeks with the 12 mg dose, compared with 2.1% for placebo — the largest weight reduction reported in any published peptide trial to date (Jastreboff et al., NEJM, 2023)

"Participants receiving higher doses of retatrutide experienced some of the largest weight reductions ever observed in pharmaceutical obesity trials." — Louis Aronne, New England Journal of Medicine (2023)

Visceral & Abdominal Fat Reduction The glucagon component specifically promotes lipolysis in visceral adipose tissue — the metabolically harmful intra-abdominal fat most strongly associated with cardiovascular disease, insulin resistance, and metabolic syndrome.

Glycaemic Control in Type 2 Diabetes

• Significant improvements in HbA1c and fasting glucose
• Meaningful reductions in cardiovascular risk factors
• Improvements in insulin sensitivity

Cardiovascular Metabolic Markers

• Reduced blood pressure
• Improved lipid profiles
• Reduction in inflammatory metabolic markers

Retatrutide also demonstrated meaningful improvements in glycaemic control and cardiovascular risk markers in the phase 2 population (Jastreboff et al., NEJM, 2023).

---

Dosing & Administration

Route: Once-weekly subcutaneous injection Doses studied in Phase 2 trials: 1 mg, 4 mg, 8 mg, 12 mg per week

Titration Schedule (as used in clinical trials):

Gradual titration is essential — it significantly reduces gastrointestinal side effects and allows the body to adapt to the triple agonist activity. Do not accelerate the titration schedule. The phase 2 trial used a dose-escalation protocol from 1 mg to 12 mg over 48 weeks, with dose-dependent weight reduction observed across all dose groups (Jastreboff et al., NEJM, 2023).

Injection Sites: Abdomen, upper thigh, or upper arm — rotate weekly

Reconstitution:

• Add bacteriostatic water to lyophilised powder
• Swirl gently — never shake
• Refrigerate at 2–8°C and use within 28 days
• Discard if solution is cloudy or contains visible particles

---

Side Effects & Safety

Retatrutide's side effect profile mirrors that of other GLP-1-based therapies, with gastrointestinal symptoms being the most common — particularly during dose escalation.

Commonly reported (especially during titration):

• Nausea — most frequent; typically peaks during dose escalation and improves significantly once the maintenance dose is stable
• Vomiting
• Diarrhoea
• Reduced appetite (often desired, but can be pronounced)
• Abdominal discomfort or bloating
• Constipation

Most GI symptoms are mild to moderate and resolve or substantially improve as the body adapts. Gradual titration is the most effective strategy for minimising these effects. The most commonly reported adverse events in the phase 2 trial were gastrointestinal in nature, including nausea, diarrhoea, and vomiting, which were generally mild to moderate and dose-dependent (Jastreboff et al., NEJM, 2023).

Monitoring during use:

• Cardiovascular markers (blood pressure, lipid profile)
• Liver enzymes and kidney function
• Glucose control — particularly important for individuals with diabetes or insulin resistance
• Adverse event tracking during each dose escalation step

Who should avoid or use with caution:

• Personal or family history of medullary thyroid carcinoma or MEN2 — glucagon receptor agonists carry a theoretical thyroid C-cell tumour risk (consistent with other GLP-1 agents); avoid use
• History of pancreatitis — incretin-based medications are contraindicated; consult your physician
• Type 1 diabetes — not appropriate; consult an endocrinologist
• Pregnancy and breastfeeding — avoid use
• Severe gastrointestinal conditions — gastroparesis or other GI motility disorders require specialist consultation

---

Synergy Stacks

Metabolic Recomposition: Retatrutide + MOTS-c MOTS-c's AMPK-pathway mitochondrial insulin sensitisation complements Retatrutide's systemic metabolic effects — particularly useful for individuals with insulin resistance or metabolic syndrome where cellular glucose utilisation is impaired.

Body Composition: Retatrutide + HGH Fragment 176-191 Retatrutide drives appetite suppression and whole-body fat metabolism via the GLP-1/GIP/glucagon triple mechanism; HGH Frag 176-191 adds targeted beta-3 adrenergic lipolysis at the adipose tissue level. A complementary dual-mechanism adipose reduction research stack.

Cellular Ageing & Metabolic Research: Retatrutide + NAD+ + Epitalon Retatrutide addresses the metabolic dimension of ageing (visceral adiposity, insulin resistance); NAD+ restores cellular energy and sirtuin function; Epitalon targets telomere biology and the pineal gland. A comprehensive metabolic longevity stack.

---

Key References

Jastreboff et al. (2023) – Phase 2 Retatrutide Obesity Trial

NEJM

---

Further Reading

For a comprehensive deep-dive into Retatrutide's clinical trial data, mechanisms, and research context, see the Riptide Health Research Article: Retatrutide — Full Research Review